Posted by Michael Wonder on 02 Jun 2023
Esperion announces submission of supplemental new drug applications to US FDA for Nexletol (bempedoic acid) tablet and Nexlizet (bempedoic acid and ezetimibe) tablet
1 June 2023 - Submitted four efficacy supplements seeking inclusion of cardiovascular disease risk reduction and expansion of LDL-cholesterol lowering.
Esperion today announced that it has submitted supplemental new drug applications to the US FDA for the Company’s oral non-statin products Nexletol and Nexlizet.
